Sinphar Pharmaceutical Co Ltd (1734):企業の財務・戦略的SWOT分析

◆英語タイトル:Sinphar Pharmaceutical Co Ltd (1734) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY0995
◆発行会社(調査会社):GlobalData
◆発行日:2020年1月
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Sinphar Pharmaceutical Co Ltd (1734) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sinphar Pharmaceutical Co Ltd (Sinphar) is a healthcare company that carries out the development, manufacture and sale of pharmaceutical drugs, healthy foods and cosmetics. The company’s pharmaceutical product portfolio includes antifungal agents, anti-hypersensitive agents, cardiovascular agents, dermatologic agents, ophthalmic agents, skincare products, health supplements and others. It also has several products in pipeline addressing dementia, dry age-related macular degeneration, triple-negative breast cancer, pancreatic cancer, genital warts and others. Sinphar offers contract manufacturing services to pharmaceutical companies for the development of new products. It has presence in China, Taiwan, Canada and other countries. Sinphar is headquartered in Tungshan, Yilan, Taiwan.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Sinphar Pharmaceutical Co Ltd – Key Facts
Sinphar Pharmaceutical Co Ltd – Key Employees
Sinphar Pharmaceutical Co Ltd – Key Employee Biographies
Sinphar Pharmaceutical Co Ltd – Major Products and Services
Sinphar Pharmaceutical Co Ltd – History
Sinphar Pharmaceutical Co Ltd – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Sinphar Pharmaceutical Co Ltd – Business Description
Sinphar Pharmaceutical Co Ltd – SWOT Analysis
SWOT Analysis – Overview
Sinphar Pharmaceutical Co Ltd – Strengths
Sinphar Pharmaceutical Co Ltd – Weaknesses
Sinphar Pharmaceutical Co Ltd – Opportunities
Sinphar Pharmaceutical Co Ltd – Threats
Sinphar Pharmaceutical Co Ltd – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Sinphar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Sinphar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Sinphar Pharmaceutical Co Ltd, Recent Deals Summary
Section 5 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Sinphar Pharmaceutical Co Ltd, Key Facts
Sinphar Pharmaceutical Co Ltd, Key Employees
Sinphar Pharmaceutical Co Ltd, Key Employee Biographies
Sinphar Pharmaceutical Co Ltd, Major Products and Services
Sinphar Pharmaceutical Co Ltd, History
Sinphar Pharmaceutical Co Ltd, Subsidiaries
Sinphar Pharmaceutical Co Ltd, Key Competitors
Sinphar Pharmaceutical Co Ltd, Ratios based on current share price
Sinphar Pharmaceutical Co Ltd, Annual Ratios
Sinphar Pharmaceutical Co Ltd, Annual Ratios (Cont...1)
Sinphar Pharmaceutical Co Ltd, Annual Ratios (Cont...2)
Sinphar Pharmaceutical Co Ltd, Interim Ratios
Sinphar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Sinphar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Sinphar Pharmaceutical Co Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Sinphar Pharmaceutical Co Ltd, Performance Chart (2014 - 2018)
Sinphar Pharmaceutical Co Ltd, Ratio Charts
Sinphar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Sinphar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Sinphar Pharmaceutical Co Ltd (1734):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Huntsman Corp (HUN):企業の財務・戦略的SWOT分析
    Huntsman Corp (HUN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Spineway SAS (ALSPW):医療機器:M&Aディール及び事業提携情報
    Summary Spineway SAS (Spineway) is a medical device company that manufactures, designs, and commercializes surgical implants and instruments. The company offers products such as thoraco-lumbar, cervical, mini invasive products and other bio materials. Its thoraco-lumbar products include mont blanc d …
  • Australian Securities & Investments Commission:企業の戦略的SWOT分析
    Australian Securities & Investments Commission - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitor …
  • Premier Biomedical Inc (BIEI):製薬・医療:M&Aディール及び事業提携情報
    Summary Premier Biomedical Inc (Premier Biomedical) is a drug development company that develops medications for debilitating and fatal illnesses. The company offers Feldetrex, a drug candidate used for the treatment of multiple sclerosis, fibromyalgia, blood sepsis and viremia, and cancer. It develo …
  • Verastem Inc (VSTM):医療機器:M&Aディール及び事業提携情報
    Summary Verastem Inc (Verastem) is a clinical-stage biopharmaceutical company with focus on the discovery, development and commercialization of drugs to treat cancer. The company’s lead product candidates include duvelisib, defactinib (VS-6063), FAK inhibitor (VS-4718) and PI3K/mTOR inhibitor (VS-55 …
  • S.C. Hidroelectrica SA:企業の戦略的SWOT分析
    S.C. Hidroelectrica SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • The Saudi Arabian Monetary Agency:企業の戦略的SWOT分析
    The Saudi Arabian Monetary Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Sygnity SA (SGN):企業の財務・戦略的SWOT分析
    Sygnity SA (SGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Arena Pharmaceuticals Inc (ARNA):企業の財務・戦略的SWOT分析
    Arena Pharmaceuticals Inc (ARNA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Upsher-Smith Laboratories Inc:企業のM&A・事業提携・投資動向
    Upsher-Smith Laboratories Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Upsher-Smith Laboratories Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • PharmaLundensis AB:製薬・医療:M&Aディール及び事業提携情報
    Summary PharmaLundensis AB (PharmaLundensis) is a pharmaceutical company that develops drugs for lung diseases. The company develops drugs for chronic obstructive pulmonary disease (COPD), chronic bronchitis and influenza-induced lung failure. It also develops EcoFilter, a system that that eliminate …
  • Vectren Corporation (VVC)-エネルギー分野:企業M&A・提携分析
    Summary Vectren Corporation (Vectren) is an energy holding company, which carries out the distribution and transmission of natural gas and electricity. Under its wholly owned subsidiary, Vectren Utility Holdings, Inc., the company operates three utilities; Vectren Energy Delivery of Indiana - North …
  • City of Hope-製薬・医療分野:企業M&A・提携分析
    Summary City of Hope (COH) is a biomedical research organization that offers cancers, diabetes and infectious diseases treatment services. The organization offers services in the fields of anesthesiology, interventional radiology, surgery, donor matching and marrow transplants, rehabilitation servic …
  • Chagala Group Limited:企業の戦略・SWOT・財務情報
    Chagala Group Limited - Strategy, SWOT and Corporate Finance Report Summary Chagala Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Ameresco Inc (AMRC):電力:M&Aディール及び事業提携情報
    Summary Ameresco, Inc. (Ameresco) provides comprehensive energy services, including energy efficiency, infrastructure upgrades, asset sustainability and renewable energy solutions. It also offers energy infrastructure facility upgrade; and development, construction and operation of renewable energy …
  • Beverages & More Inc:企業の戦略的SWOT分析
    Beverages & More Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • NewOcean Energy Holdings Ltd (342):企業の財務・戦略的SWOT分析
    NewOcean Energy Holdings Ltd (342) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Cytodyn Inc (CYDY):企業の財務・戦略的SWOT分析
    Summary Cytodyn Inc (Cytodyn), formerly RexRay Corp, is a biotechnology company. It develops and commercializes monoclonal antibodies for the treatment of Human Immunodeficiency Virus (HIV) infections. It is investigating Leronlimab (PRO 140), a fully humanized IgG4 monoclonal antibody directed agai …
  • TDC A/S:企業の戦略・SWOT・財務分析
    TDC A/S - Strategy, SWOT and Corporate Finance Report Summary TDC A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • GridPoint, Inc.:電力:M&Aディール及び事業提携情報
    Summary GridPoint, Inc. (GridPoint), a subsidiary of Twenty First Century Utilities LLC, is a smart buildings technology company. It provides visibility into facility operations, and assists customers to automate and control sites, lower energy spend, and manage day-to-day operations. The company pr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆